CN102614111B - 氨基葡萄糖的凝胶剂及其制备方法 - Google Patents
氨基葡萄糖的凝胶剂及其制备方法 Download PDFInfo
- Publication number
- CN102614111B CN102614111B CN 201210097693 CN201210097693A CN102614111B CN 102614111 B CN102614111 B CN 102614111B CN 201210097693 CN201210097693 CN 201210097693 CN 201210097693 A CN201210097693 A CN 201210097693A CN 102614111 B CN102614111 B CN 102614111B
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- gel
- percent
- preparation
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 52
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title abstract description 33
- 238000001879 gelation Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract description 11
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 10
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 9
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 5
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 20
- 229920002125 Sokalan® Polymers 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 14
- 229960001631 carbomer Drugs 0.000 claims description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 12
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 12
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 7
- 229960004926 chlorobutanol Drugs 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- -1 alcohol compound Chemical class 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 229940069338 potassium sorbate Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical group [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 239000004909 Moisturizer Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001333 moisturizer Effects 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 42
- 239000008213 purified water Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000013521 mastic Substances 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001835 salubrious effect Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210097693 CN102614111B (zh) | 2012-04-05 | 2012-04-05 | 氨基葡萄糖的凝胶剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210097693 CN102614111B (zh) | 2012-04-05 | 2012-04-05 | 氨基葡萄糖的凝胶剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102614111A CN102614111A (zh) | 2012-08-01 |
CN102614111B true CN102614111B (zh) | 2013-11-06 |
Family
ID=46554566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210097693 Expired - Fee Related CN102614111B (zh) | 2012-04-05 | 2012-04-05 | 氨基葡萄糖的凝胶剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102614111B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103751305B (zh) * | 2013-12-11 | 2016-03-30 | 内蒙古元和药业股份有限公司 | 一种治疗类风湿关节炎的药物及其制备方法 |
CN110507602B (zh) * | 2019-09-09 | 2021-05-25 | 山东润德生物科技有限公司 | 一种氨基葡萄糖的凝胶剂及其制备方法 |
CN111000899A (zh) * | 2019-12-31 | 2020-04-14 | 河南科高中标检测技术有限公司 | 一种具有抗炎镇痛活性的凝胶膏及其制备方法与应用 |
CN112169713A (zh) * | 2020-09-09 | 2021-01-05 | 江南大学 | 一种n-烷基乳糖胺表面活性剂小分子醇凝胶及其制备方法 |
CN114191405B (zh) * | 2021-11-06 | 2023-02-03 | 山东润德生物科技有限公司 | 一种凝胶型氨基葡萄糖制剂的制备方法与应用 |
CN116459238B (zh) * | 2023-05-08 | 2023-12-05 | 乐明药业(苏州)有限公司 | 一种促进氨基葡萄糖持续释放的组合物及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909911A (zh) * | 2003-10-01 | 2007-02-07 | 浩鼎生技公司 | 通过给予氨基糖治疗哺乳动物的疾病状态及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827937A (en) * | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
JP5184726B2 (ja) * | 2001-10-16 | 2013-04-17 | 帝國製薬株式会社 | グルコサミン含有パップ剤 |
US20070142326A1 (en) * | 2004-09-30 | 2007-06-21 | Youe-Kong Shue | Treatment of a condition in a mammal with administration of aminosugar and uses thereof |
-
2012
- 2012-04-05 CN CN 201210097693 patent/CN102614111B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909911A (zh) * | 2003-10-01 | 2007-02-07 | 浩鼎生技公司 | 通过给予氨基糖治疗哺乳动物的疾病状态及其用途 |
Non-Patent Citations (2)
Title |
---|
洪育萍 等.硫酸氨基葡萄糖凝胶质量控制标准的初步研究.《中国医药指南》.2010,第8卷(第19期),250页左栏. |
硫酸氨基葡萄糖凝胶质量控制标准的初步研究;洪育萍 等;《中国医药指南》;20100731;第8卷(第19期);250页左栏 * |
Also Published As
Publication number | Publication date |
---|---|
CN102614111A (zh) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102614111B (zh) | 氨基葡萄糖的凝胶剂及其制备方法 | |
JP6434104B2 (ja) | ジクロフェナク製剤 | |
KR102184245B1 (ko) | 케토프로펜 국소 조성물 | |
CN1684709A (zh) | 局部用的药物学载体 | |
CN102048678A (zh) | 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用 | |
JP2014513132A (ja) | イブプロフェンの経皮組成物およびその使用方法 | |
CN100417376C (zh) | 草乌甲素巴布剂 | |
Dua et al. | Aceclofenac topical dosage forms: in vitro and in vivo characterization | |
CN101455654A (zh) | 精氨酸布洛芬凝胶剂及其制备方法 | |
WO2023277075A1 (ja) | ヘパリン類似物質、および、ロキソプロフェン又はその塩を含有する皮膚外用剤 | |
WO1992016237A1 (fr) | Composition soulageant les irritations cutanees et preparation pour administration percutanee a usage externe contenant ladite composition | |
RU2582278C2 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей | |
CN102872288B (zh) | 一种治疗风湿骨痛乳香风湿气雾剂及其制备方法 | |
CN100502850C (zh) | 辣椒总碱类化合物与β-环糊精或β-环糊精衍生物的药用组合物 | |
JP4835411B2 (ja) | アダパレン含有外用剤組成物 | |
CN110139641B (zh) | 外用组合物 | |
JP2004067562A (ja) | 外用組成物 | |
JP5338030B2 (ja) | アダパレン含有外用剤組成物 | |
CN102697703B (zh) | 一种吡罗昔康凝胶制剂及其制备方法 | |
CN105663605A (zh) | 一种对皮肤、粘膜有保护健康作用的大蒜乳剂凝胶制剂 | |
CN110339169A (zh) | 包覆维生素d和维生素k的纳米囊泡制剂及其应用 | |
Munshi et al. | Formulation and Evaluation of Diclofenac gel | |
JP7592396B2 (ja) | ロキソプロフェン及び可溶化剤を含有する皮膚外用剤 | |
JPH01102024A (ja) | 外用皮膚疾患治療剤 | |
JP2024055826A (ja) | ロキソプロフェン又はその塩、およびサリチル酸類を含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Li Shuning Document name: Notification that Application Deemed not to be Proposed |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151026 Address after: The western part of Yancheng District Songjiang road 462300 Luohe city in Henan Province Patentee after: Yu Yuan Pharmaceutical Co.,Ltd. Address before: Wuzhong District Wuzhong road in Suzhou city of Jiangsu Province, No. 1336 D block 215104 Patentee before: SUZHOU FREEMEN PHARMACEUTICALS Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131106 |